


Practical Implementation of AI Models for Regression (1): Dataset Exploration and Problem Formulation

회귀 인공지능 모델 개발 실습 (1): 데이터 및 예측 문제

Ageing

- Process of becoming older
 - Refers mainly to humans
- Biological basis [\[Jin, 2010\]](#)
 - Neither theory appears to be fully satisfactory
 - Two main theoretical categories:
 - Genetically programmed
 - Biological timetable, perhaps a continuation of childhood growth and development
 - Damage or error-related
 - Environmental assaults to living organisms

- Hallmarks of ageing [\[Guo et al., 2022\]](#)
 - Genomic instability
 - Telomere dysfunction
 - Epigenetic alterations
 - Loss of proteostasis
 - Compromise of autophagy
 - Mitochondrial dysfunction
 - Cellular senescence
 - Stem cell exhaustion
 - Altered intercellular communication
 - Deregulated nutrient sensing




[Guo et al., 2022]

Ten hallmarks of ageing subdivided into three categories

- Changes by ageing
 - Accumulation of a wide variety of molecular and cellular damage over time
 - gradual decrease in physical and mental capacity
 - growing risk of disease
 - death
 - Neither linear nor consistent
 - Only loosely associated with an individual's age in years
 - Often associated with other life transitions such as retirement, relocation to more appropriate housing, and the death of friends and partners

- Population ageing
 - Shift in distribution of a country's population towards older ages
 - Increasing median age in a population
 - By 2030, 1 in 6 people in the world will be aged 60 years or over
[\[https://www.who.int/news-room/fact-sheets/detail/ageing-and-health\]](https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)
 - Because of declining fertility rates and rising life expectancy
 - Started in high-income countries and now extended to low- and middle-income countries



[\[http://study-aids.co.uk/dissertation-blog/population-ageing/\]](http://study-aids.co.uk/dissertation-blog/population-ageing/)

Size and proportion of the global population as related to age over time

- Healthy ageing [<https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>]
 - Proposed by the World Health Organization
 - Importance of an individual's healthspan (years lived in good health) in their lifespan (total years lived) with longevity
 - Related to non-random diversity seen in older age
 - Operationalises health as functional ability, which results from the interactions of intrinsic capacity and the environments
 - Although some of the variations in older people's health are genetic, most is due to their physical and social environments as well as their personal characteristics

Biological Age

- Two types of age
 - Chronological age
 - Number of years an individual has been alive
 - Unchangeable
 - Biological age
 - How old an individual's cells and tissues appear to be based on their current condition
 - May be reversed

CHRONOLOGICAL AGE

- The number of years that have passed since our birth.
- Cannot be influenced by lifestyle and eating habits.
- Has little relevance to how you feel and function.




BIOLOGICAL AGE

- How old our cells really are, therefore, our real age
- Can be reversed by attending to your health
- The most important component to the aging process

[<https://rejuvenate.com/truage/>]

Chronological vs. biological age

- Departure of biological age from chronological age
 - May exhibit greatly different susceptibilities to age-related diseases and death for individuals of the same chronological age
 - Likely reflective of differences in underlying biological ageing processes
- Biological age as a biomarker of ageing
 - Individual-level measure of ageing that captures inter-individual differences in the timing of disease onset, functional decline, and death over the life course
 - Crucial to enable evaluation of interventions aimed at promoting healthier aging, by providing a measurable outcome



[Haupt et al., 2022]

Factors that have the potential to advance or delay ageing processes

- How biological age is determined
 - Often by assessing an individual's genetic material
 - Telomeres (repeats of a hexameric DNA sequence capping the end of chromosomes)
 - Shorter telomeres → older biological age
 - DNA methylation (DNAm, hypo- and hyper-methylation changes at many regions across the genome)



| TruAge™ vs. Everyone Else | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------|---------------|
| What we do that Zymo and Elysium don't | | | |
| While Zymo (MyDNAge) and Elysium (Index) market their biological age test to consumers all over the world, there are a few things they don't do. | | | |
| | TruAge™ | MyDNAge | Index |
| Test over 900,000 Loci | ✓ | ✗ | ✗ |
| Custom Algorithm | ✓ | ✗ | ✗ |
| Track your lab and health information in one place | ✓ | ✗ | ✗ |
| Validated Collection Method | ✓ | ✗ | ✗ |
| Additional Testing | TruTelomere™ | ✗ | ✗ |
| Report | 50+ Pages of Interpreted Data and Clinical Recommendations | 1 Page Report | 3 Page Report |
| Time it Takes to Report Results | 4-6 Weeks | 6-8 Weeks | 6+ Weeks |

– A combination of numerous potential markers that specifically measures all important aspects of ageing processes may be the key to a valid composite biomarker of ageing [\[Hartmann et al., 2021\]](#)

- Routine laboratory
- Epigenetic
- Non-epigenetic
- Physical capability
- Organ function
- Cellular senescence

| Potential biomarkers | Material | Age linked processes [#] | e-score | rc-score* | c-score |
|----------------------------------------------------------------|-------------------------|------------------------------------------------------|---------|-----------|---------|
| Lymphocytes/WBC [CDC] [PA] | blood/EDTA | Inflammation autoimmune disorders | - | 202 | 2240 |
| Insulin | blood/serum | Diabetic state | -- | 148 | 1143 |
| Glucose/glucose fastened [PA] | blood/glucose monovette | Diabetic state | - | 111 | 1175 |
| C-reactive protein (CRP/hsCRP) [IA] [PA] | blood/plasma | Inflammation, cancer, cardiovascular disease | - | 71 | 1146 |
| Cholesterol | blood/plasma | Cardiovascular disease | - | 67 | 896 |
| Albumin [PA] | blood/plasma | Kidney and liver dysfunction | - | 65 | 1062 |
| IL6 [IA] | blood/plasma | Inflammation | - | 58 | 979 |
| Tumor necrosis factor alpha (TNF α) [IA] | blood/serum | Inflammation, cancer | -- | 51 | 751 |
| Hemoglobin [CDC] | blood/EDTA | Anemia, other hematopoietic disorders | - | 39 | 471 |
| Insulin-like growth factor 1 (IGF-1) | blood/serum | Metabolic disease | -- | 29 | 263 |
| LDL-cholesterol | blood/plasma | Cardiovascular disease | - | 24 | 280 |
| Triglycerides | blood/plasma | Cardiovascular disease | - | 23 | 498 |
| HDL-cholesterol | blood/plasma | Cardiovascular disease | - | 23 | 349 |
| Creatinine [PA] | blood/plasma | Kidney dysfunction | - | 19 | 479 |
| Monocytes | blood/EDTA | Inflammation | - | 16 | 378 |
| Glycated hemoglobin (HbA1c) | blood/EDTA | Diabetic state | - | 13 | 220 |
| Cystatin C | blood/plasma | Kidney dysfunction | - | 12 | 142 |
| N-terminal prohormone of brain natriuretic peptide (NT-proBNP) | blood/EDTA | Heart failure | - | 10 | 119 |
| Alkaline phosphatase [PA] | blood/plasma | Liver damage, bone disorder | - | 9 | 252 |
| Hematocrit/RBC [CDC] | blood/EDTA | Anemia | - | 8 | 159 |
| D-dimer | blood/citrate monovette | Hypercoagulable state | - | 8 | 91 |
| IL8 [IA] | blood/plasma | Inflammation | -- | 7 | 164 |
| Plasminogen activator inhibitor-1 (PAI1) | blood/EDTA | Prothrombotic state in cancer and other acute phases | -- | 6 | 72 |
| Bilirubin | blood/plasma | Liver dysfunction | - | 5 | 46 |
| Urea | blood/plasma | Renal dysfunction | - | 3 | 137 |
| IL15 | blood/plasma | Inflammation | -- | 3 | 55 |
| Mean corpuscular volume/MCV [CDC] [PA] | blood/EDTA | Anemia, other hematopoietic disorders | - | 2 | 42 |
| Mean corpuscular hemoglobin concentration/MCHC [CDC] | blood/EDTA | Anemia, other hematopoietic disorders | - | 2 | 32 |
| CD4/CD8 ratio | blood/EDTA | Immune deficiency, autoimmunity | -- | 1 | 103 |
| C-peptide (preferable to insulin) | blood/serum | Diabetic state | - | 1 | 32 |
| IL1- β [IA] | blood/plasma | inflammation | -- | 1 | 5 |

* rows are sorted by rc-score.

[#] frequently mentioned general or disease-linked processes.

[IA] = inflammaging

[PA] = Phenotypic Age

[CDC] = complete blood count

[Hartmann et al., 2021]

Routine laboratory biomarkers of ageing

| Potential biomarkers | Material | Methods | Age linked processes [#] | e-score | rc-score* | c-score |
|-------------------------------------------------|------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------|---------|-----------|---------|
| Telomere length (TL): | | | Morbidity, mortality, cell stress | | 191 | 932 |
| Average TL | DNA | Q-PCR, TRF, TCA | | -- | | ** |
| TL structure | DNA | Q-FISH, Flow-FISH | | --- | | ** |
| Shortest TL | DNA | STELA, TeSLA | | --- | | ** |
| DNA damage | DNA | Various methods | Morbidity, mortality | -- | 174 | 713 |
| Reactive oxygen species (ROS) | Tissue mitochondria | Various methods | Morbidity, cell stress, DNA/protein damage | --- | 168 | 712 |
| Mitochondrial dysfunction | living cells, mitochondrial DNA | Various methods | Morbidity, mortality, neurodegenerative diseases | --- | 86 | 289 |
| EVs (extracellular vesicles) | blood/plasma, liquor, cell culture supernatant | Immuno-histochemistry Western Blot, FACS | Cellular senescence, cancer | --- | 65 | 194 |
| Autophagy | cells, cell extract | Electron microscopy immunoblotting flow cytometry | Morbidity, cancer, Parkinson's and Alzheimer's disease | --- | 46 | 207 |
| Transforming growth factor beta (TGF- β) | blood/serum | ELISA | Inflammation, fibrosis, cellular senescence, cancer | -- | 45 | 315 |
| Telomerase activity | cell extract, DNA | PCR-ELISA, TRAP | Morbidity, mortality, tumor progression | --- | 41 | 169 |
| Gut microbiome | fecal specimen | Next generation sequencing | Morbidity, mortality | -- | 29 | 101 |
| α -Klotho | blood/plasma tissue | Immuno-histochemistry ELISA | Morbidity, mortality, renal function | -- | 20 | 107 |
| Adiponectin | blood/plasma blood/EDTA | ELISA | Morbidity, mortality, frailty, metabolic syndrome, liver cirrhosis, diabetes type 2 | - | 14 | 217 |
| Sirtuin 1 (SIRT1) | blood/serum | ELISA immuno-histochemistry PCR | Morbidity, mortality, inflammation, cancer | -- | 12 | 112 |
| Growth differentiation factor 15 (GDF15) | blood/plasma | Proteomics immunoassays | Morbidity, organ damage (liver, heart, kidney) | -- | 12 | 63 |
| Sirtuin 6 (SIRT6) | blood/serum | ELISA immuno-histochemistry PCR | Morbidity, mortality, diabetic risk, arthritis | -- | 4 | 50 |
| Growth differentiation factor 11 (GDF11) | blood/plasma | Proteomics immunoassays | Morbidity | -- | 3 | 22 |
| CXCL1 | blood/plasma | Immunoassays, ELISA | Immune response, inflammation, cancer, Alzheimer's disease | -- | 0 | 15 |
| Skin microbiome | skin swab | Next generation sequencing | Morbidity, mortality | -- | 0 | 4 |

* rows are sorted by rc-score.

** included in the c-score of TL.

[#] frequently mentioned general or disease-linked processes.

[Hartmann et al., 2021]

Research laboratory biomarkers based on non-epigenetic measurements

| Potential biomarkers | Material | Methods | Prediction | e-score | rc-score | c-score* |
|------------------------------------|---------------------------------|------------------------------------------------------------------------------|----------------------|---------|----------|----------|
| DNA methylation and aging clocks: | | | | | n.a. | 2158 |
| Horvath's clock | DNA (broad spectrum of tissues) | DNA methylation analysis | Chronological age | -- | n.a. | 214 |
| Hannum's clock | DNA (blood) | | Chronological age | -- | n.a. | 190 |
| DNAm GrimAge | DNA (blood) | | Biological age | -- | n.a. | 31 |
| DNAm PhenoAge | DNA (blood) | | Biological age | -- | n.a. | 26 |
| Weidner clock | DNA (blood) | | Chronological age | -- | n.a. | 8 |
| EpiTOC | DNA (blood) | | Biological age | --- | n.a. | 2 |
| miRNA (microRNA) | RNA (blood/plasma PBMCs) | Next generation sequencing microarrays | Morbidity, mortality | --- | 198 | 635 |
| Non-coding RNA expression profiles | RNA | RNA sequencing | Chronological age | --- | 167 | 602 |
| exRNA (extracellular RNA) | blood/plasma | Next generation sequencing | Morbidity, mortality | --- | 25 | 119 |
| Histone modifications: | | | | | 36 | 73 |
| H4K20 methylation | | DNA methylation analysis mass spectrometry, HPLC, ChIP Immunohisto-chemistry | Cell stress | --- | n.a. | n.a. |
| H4K16 acetylation | | | | --- | n.a. | n.a. |
| H3K4 methylation | protein extract | | | --- | n.a. | n.a. |
| H3K9 methylation | from tissue DNA | | | --- | n.a. | n.a. |
| H3K27 methylation | | | | --- | n.a. | n.a. |
| Chromatin remodeling | DNA | Chromatin remodeling assays | Chronological age | --- | 13 | 26 |

* rows are sorted by c-score.

n.a.: not assigned due to high variation of terminology in literature.

[Hartmann et al., 2021]

Research laboratory biomarkers based on epigenetic measurements

| Potential biomarkers | Method | Age linked processes [#] | Domain | e-score | rc-score* | c-score |
|----------------------------|---------------------|-----------------------------------|-----------------------|---------|-----------|---------|
| Physical capability | | | | | | |
| Grip strength | Physical exam | Mortality, morbidity | Strength | -- | 11 | 229 |
| Walking speed | Physical exam | Mortality, morbidity | Locomotor function | -- | 3 | 106 |
| Standing balance | Physical exam | Mortality, morbidity | Balance | -- | 1 | 26 |
| Timed up and go test | Physical exam | Mortality, morbidity | Locomotor function | -- | 0 | 11 |
| Organ function | | | | | | |
| Atherosclerotic lesions | IMT, ultrasound | Mortality, CAD | Cardiovascular system | -- | 158 | 680 |
| Muscle mass | MRI | Mortality, cardiovascular risk | Body composition | -- | 81 | 495 |
| Systolic blood pressure | Auscultatory method | Mortality, cardiovascular risk | Cardiovascular system | -- | 65 | 844 |
| Cognitive function | Various | Mortality, morbidity | Brain function | --- | 56 | 581 |
| Body mass index | Calculated | Mortality CAD | Body composition | -- | 24 | 1280 |
| Bone density | Bone density test | Mortality, morbidity | Body composition | -- | 17 | 84 |
| Lung function | Spirometry | Mortality, morbidity | Respiratory system | -- | 16 | 84 |
| Waist circumference | Tape measure | Mortality, cardiovascular risk | Body composition | -- | 3 | 202 |
| General well being | | | | | | |
| Health assessments | Questionnaire | Mortality, morbidity | General | -- | n.a. | n.a. |

* rows are sorted by c-score.

[#] frequently mentioned general or disease-linked.

n.a.: not assigned due to high variation of terminology in literature.

[Hartmann et al., 2021]

Non-blood physical capability and organ function biomarkers

| Potential biomarker | | Material and Methods | e-score | rc-score* | c-score |
|----------------------------------|------------------------------------------|-------------------------------------------------------------------|---------|-----------|---------|
| SASP | Cytokines (e.g., IL-6, IL-7, IL-15) | ELISA from Serum or EDTA plasma samples proteomics | --° | 442 | 2646 |
| | | | --° | n.a. | n.a. |
| | | | --° | | |
| | | | -- | | |
| | Chemokines (e.g., IL-8, CCL3, CCL4) | | | n.a. | n.a. |
| Cell cycle arrest | Growth factors (e.g., GDF-15, activin A) | | | n.a. | n.a. |
| | p53 | qPCR from blood samples/staining of cultured cells/flow cytometry | -- | 66 | 561 |
| | | NGS/microarray | -- | | |
| | p16 | | | 27 | 422 |
| | p21 | | | 21 | 435 |
| SA-βGal | | Microscopy/flow cytometry | --- | 9 | 359 |
| SAHF | Histone fragments (H3K9Me2, HP1γ) | DAPI/heterochromatin staining | ---° | 3 | 19 |
| Lamin B1 | | Immunohistochemistry Western Blot | --- | 0 | 12 |
| Cell morphology (e.g., progerin) | Cell shape | Microscopy of cultured cells | --- | n.a. | n.a. |

* rows are sorted by rc-score.

° on average (detailed in **Supplementary Table 1, 5**).


n.a.: not assigned due to high variation of terminology in literature.

[Hartmann et al., 2021]

Biomarkers associated with cellular senescence

Brain Age

- Biological age estimated from information usually derived from brain MRI data
- Sums up the progression of ageing processes in the brain
 - Reflects relatively advanced or delayed brain maturation, while all individuals' brains undergo the general progression such as the thinning of grey matter




[\[https://www.brainkey.ai/blog/brain-age-how-we-calculate-it-and-what-it-means\]](https://www.brainkey.ai/blog/brain-age-how-we-calculate-it-and-what-it-means)

Typical brain images for young (22 years) and old (83 years) individuals



- Brain age gap (BAG, also called brain-predicted age difference, delta, etc.)
 - Difference between brain age and chronological age: $BAG = \text{estimated brain age} - \text{chronological age}$
 - Indicates whether an individual's brain appears to have aged more or less than the population average for their actual chronological age
 - $BAG > 0$: advanced or premature brain ageing
 - Related to functional impairment [Liem et al., 2017], brain diseases such as Alzheimer's disease [Yin et al., 2023], Parkinson's disease [Eickhoff et al., 2021], schizophrenia [Nenadic et al., 2017], stroke [Egorova et al., 2019], epilepsy [Sone et al., 2021], and diabetes mellitus [Franke et al., 2013], and mortality [Cole et al., 2017]
 - $BAG < 0$: delayed or resilient brain ageing

**Brain aging differences between
objective cognitive impairment (OCI) groups
stacked-multimodal**



[Liem et al., 2017]


Premature brain ageing ($BAG > 0$) in cognitive impairment



MCI, mild cognitive impairment
AD, Alzheimer's disease
FTD, frontotemporal dementia
DLB, dementia with Lewy bodies


[Lee et al., 2022]

Advanced brain ageing (BAG > 0) in brain diseases




[Cole et al., 2017]

Comparison of survival rate: low BAG vs. high BAG



[Cole et al., 2017]

Receiver operator characteristic (ROC) curves for four survival models



[Park et al., In Review]

Resilient brain ageing (BAG < 0) in superaging

Regression in Machine Learning

- Models the relationship between input features (predictors) and the target variable (dependenct variable)
- Purpose
 - Understanding the relationship between input features and continuous target variables
 - Predicting continuous target values for new sets of input features

- Supervised learning technique for predicting continuous output values
 - Traditional methods
 - Linear regression: simple, multiple
 - Non-linear regression: polynomial, support vector regression
 - Ensemble methods
 - Bagging-based methods: random forests, extra trees
 - Boosting-based methods: AdaBoost (Adaptive Boosting), Gradient Boosting Machines (GBM), XGBoost (eXtreme Gradient Boosting), LightGBM, CatBoost (Categorical Boosting)
 - Stacking: combining predictions from multiple models

– Deep learning-based regression

- Feedforward Neural Network (FNN) / Multilayer Perceptron (MLP)
- Specialized architectures
 - Convolutional Neural Network (CNN) for spatial data regression
 - Recurrent Neural Network (RNN) and Long Short-Term Memory (LSTM) for sequential data regression
 - Transformer-based models for complex sequential data regression

– Hybrid approaches

- Combining traditional methods with ensemble techniques or neural networks
- Automated machine learning (AutoML) systems incorporating various regression techniques

- Types of regression problems
 - Based on the nature of the relationship:
 - Linear regression: modeling linear relationships
 - Nonlinear regression: modeling complex, nonlinear relationships
 - Based on the number of output variables
 - Univariate regression: predicting a single output variable
 - Multivariate regression: predicting multiple output variables simultaneously

- Regression performance
 - Mean Absolute Error (MAE)
 - Average of absolute differences between predicted and actual values
 - Range: 0 to ∞ (lower is better)
 - In the same unit as the target variable
 - Less sensitive to outliers
 - Mean Squared Error (MSE)
 - Average of squared differences between predicted and actual values
 - Range: 0 to ∞ (lower is better)
 - Penalizes larger errors more heavily
 - Harder to interpret as being in squared units
 - Sensitive to outliers

– Root Mean Squared Error (RMSE)

- Square root of MSE
- Range: 0 to ∞ (lower is better)
- In the same unit as the target variable
- Still sensitive to outliers, but less than MSE

– R-squared (coefficient of determination)


- Proportion of variance in the target variable predictable from input features
 - $R^2 = 1 - (\text{residual sum of squares} / \text{total sum of squares})$
- Range: $-\infty$ (can be negative for poorly fitting models, especially when the model is not fitted with an intercept term) via 0 (just predicting the mean) to 1 (perfect fit)
- Represents the fraction of variance explained by the model
 - $R^2 = 1 - \text{Fraction of Variance Unexplained (FVU)}$

– Correlation coefficient

- Measure of linear correlation between predicted and actual values
- Range: -1 (perfect negative correlation) via 0 (no linear correlation) to 1 (perfect positive correlation)
- Measures strength and direction of linear relationship

Brain Age Estimation

- Process of predicting an individual's biological brain age based on brain features usually extracted from MRI data
- Aimed to assess brain health status
 - Life-long, multidimensional, dynamic state consisting of cognitive, emotional, and motor domains underpinned by physiological processes [\[Chen et al., 2022\]](#)



[Franke et al., 2010]

Estimation of brain age

- Methodology
 - Models chronological age using various brain features
 - Develops brain age estimation models using supervised learning algorithms
- Input data
 - Single or multi-modal brain MRI data, including structural MRI (sMRI), functional MRI (fMRI), and diffusion-weighted MRI (dMRI)
 - Quantitative features such as brain volume, cortical thickness, or white matter integrity

- Applications
 - Assessment of various brain functions, including cognitive and motor functions
 - Early diagnosis of neurodegenerative diseases (e.g., Alzheimer's disease)
 - Development of personalized intervention strategies for brain health improvement

Human Connectome Project (HCP)


- Launched in 2009 as a Blueprint Grand Challenge by the National Institutes of Health in the US
- Maps the neural pathways that underlie human brain function
 - To identify functionally distinct subdivisions of the human brain
 - To understand the relationships among the subdivisions
- Acquires and shares data about the structural and functional connectivity of the human brain

- HCP original study
 - HCP Young Adult (HCP-YA)
 - Age: 22-35 years
 - 1200 subjects data release (S1200)
 - Released on 1 March 2017
 - 1,206 healthy young adult participants collected in 2012-2015
 - Imaging and behavioural data
 - 3T MRI data for 1,113 participants
 - 3T HCP protocol (MRI and behaviour) retest data for 46 participants
 - Multimodal 7T MRI data for 184 participants
 - S1200 extensively processed functional MRI data
 - Released on 21 July 2017

- HCP lifespan studies
 - Lifespan developing human connectome project
 - Age: 20-44 weeks post-conception
 - Lifespan baby connectome project
 - Age: 0-5 years
 - HCP Development (HCP-D)
 - Age: 5-21 years
 - HCP Aging (HCP-A)
 - Age: 36-100 years


– Lifespan 2.0 release

- Released on 26 February 2021
- HCP-A & HCP-D
 - HCP-A: 725 healthy participants
 - HCP-D: 652 healthy participants
 - 22+ TB of data per project
- Imaging and behavioural data at cross-sectional visit 1 (V1)
 - Unprocessed V1 imaging data for all included modalities
 - Preprocessed structural and functional imaging data
 - Non-imaging demographic and behavioral assessment data



HUMAN
Connectome
PROJECT

Human Connectome Project Milestones



[Elam et al., 2021]

Milestones over the HCP timeline


Dataset

- HCP-A dataset ($n = 722$)
 - Training set: $n = 660$
 - Maps from sMRI data: `train/{Brain,GM,WM,CSF}/001-660.nii.gz`
 - Maps from dMRI data: `train/{FA,MD,AD,RD}/001-660.nii.gz`
 - Sex (0 = female, 1 = male): `train/Subjects.csv: Sex`
 - Age (in years): `train/Subjects.csv: Age`


– Test set: $n = 62$

- Maps from sMRI data: `test/{Brain,GM,WM,CSF}/001-062.nii.gz`
- Maps from dMRI data: `test/{FA,MD,AD,RD}/001-062.nii.gz`
- Sex (0 = female, 1 = male): `test/Subjects.csv: Sex`
- Age (in years): hidden


Training set






Test set



Distribution of age and sex for training and test sets



- Preprocessing of sMRI data
 - Correction for intensity non-uniformity (bias field)
 - Segmentation into grey matter, white matter, and cerebrospinal fluid
 - Normalisation to the Montreal Neurological Institute (MNI) template brain space



Dimensions: $208 \times 300 \times 320$

Voxel depth: 32-bit real

Voxel size: $0.8 \text{ mm} \times 0.8 \text{ mm} \times 0.8 \text{ mm}$







Image intensity distribution



Mixture of Gaussians model




Segmentation into different tissues




- Maps from sMRI data
 - Brain map in the MNI template brain space
 - Grey matter (GM) probability (partial volume fraction) map in the MNI template brain space
 - White matter (WM) probability (partial volume fraction) map in the MNI template brain space
 - Cerebrospinal fluid (CSF) probability (partial volume fraction) map in the MNI template brain space


Brain



GM



WM



CSF



1 mm:

Dimensions: $157 \times 189 \times 156$


Voxel size: $1.0 \text{ mm} \times 1.0 \text{ mm} \times 1.0 \text{ mm}$

2 mm:


Dimensions: $79 \times 95 \times 79$

Voxel size: $2.0 \text{ mm} \times 2.0 \text{ mm} \times 2.0 \text{ mm}$

Maps from sMRI data



- Processing of dMRI data
 - Correction for head motion, eddy current-induced distortion, and susceptibility artifact (B0 inhomogeneity-induced distortion)
 - Diffusion tensor modelling
 - Computation of diffusion tensor metrics
 - Normalisation to the MNI template brain space








99 volumes:

Dimensions: $140 \times 140 \times 92$

Voxel depth: 32-bit real


Voxel size: $1.5 \text{ mm} \times 1.5 \text{ mm} \times 1.5 \text{ mm}$








[<https://www.blog.brainsightai.com/post/from-dti-to-hardi>]

Diffusion tensor modelling











$$FA = \sqrt{\frac{1}{2}} \cdot \frac{\sqrt{(\lambda_1 - \lambda_2)^2 + (\lambda_2 - \lambda_3)^2 + (\lambda_3 - \lambda_1)^2}}{\sqrt{(\lambda_1)^2 + (\lambda_2)^2 + (\lambda_3)^2}}$$




[DeSouza et al., 2016]

Computation of diffusion tensor metrics




- Maps from dMRI data
 - Fractional anisotropy (FA) map in the MNI template brain space
 - Mean diffusivity (MD) map in the MNI template brain space
 - Axial diffusivity (AD) map in the MNI template brain space
 - Radial diffusivity (RD) map in the MNI template brain space


FA




MD



AD



RD



1 mm:

Dimensions: $157 \times 189 \times 156$

Voxel size: $1.0 \text{ mm} \times 1.0 \text{ mm} \times 1.0 \text{ mm}$

2 mm:

Dimensions: $79 \times 95 \times 79$

Voxel size: $2.0 \text{ mm} \times 2.0 \text{ mm} \times 2.0 \text{ mm}$

Maps from dMRI data

- Target variable
 - Age (in years)
- Brain age estimation performance
 - MAE for the test set ($n = 62$)
 - Average of absolute differences between predicted and actual ages across the test set
 - Ranges from 0 to ∞ (lower is better)